Study of JK-1201I for triple-negative breast cancer with brain metastases
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called JK-1201I for people with triple-negative breast cancer that has spread to the brain. The drug is given as a treatment to see if it can shrink or control the brain tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with triple-negative breast cancer that has spread to the brain.
- You have already tried at least one chemotherapy regimen that included anthracyclines and taxanes.
- You are able to care for yourself (ECOG performance status of 0 or 1).
- You have not had certain cancer treatments in the last 4 weeks.
- You are not pregnant or breastfeeding and agree to use contraception during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
This trial tests a new drug, MR001, for people with triple-negative breast cancer that has come back or spread. It's for those who've already tried at least one type of treatment.
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
This trial tests a new drug called JK-1201I combined with the standard chemotherapy temozolomide after you finish your initial radiation and chemo. It is for people with newly diagnosed glioblastoma who have had most of their tumor removed and are now ready for the next phase of treatment.
This trial is testing a new treatment (JK-1201I) against a standard chemotherapy (topotecan) for people with extensive-stage small cell lung cancer that has come back after first-line treatment. The goal is to see if the new treatment works better at controlling the cancer.
This trial tests a new drug called JS212, given alone or with other medicines, for people with advanced triple-negative breast cancer that has not spread too much before. It aims to see if the drug can shrink tumors or slow the disease.
Hear when a new Brain Metastasases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.